Higher Tisagenlecleucel Doses May Improve Outcomes in Youth With B-ALL

TUESDAY, Aug. 9, 2022 -- For pediatric patients with B-cell acute lymphoblastic leukemia, higher doses of tisagenlecleucel, the chimeric antigen receptor T (CAR T)-cell therapy targeting CD19, are associated with improved survival, according to a...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news